This site is intended for health professionals only

Bexotegrast significantly improves lung function in idiopathic pulmonary fibrosis

Bexotegrast in patients with idiopathic pulmonary fibrosis has been shown to produce a significant improvement in forced vital capacity

In press release by the manufacturer, Pilant Therapeutics, interim data from a Phase IIa randomised, placebo-controlled trial, showed that bexotegrast at a daily dose of 320mg, achieved a statistically significant mean increase in forced vital capacity (FVC) after 12 weeks in patients with idiopathic pulmonary fibrosis.

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by scarring of unknown cause, giving rise to dyspnoea and a non-productive cough. The data in the press release is derived from the INTEGRIS-IPF trial, a multi-national, randomised, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of once-daily bexotegrast in people with IPF. The study included four doses (40, 80, 160 and 320mg) and patients were randomised 3:1 (active vs placebo). Although the primary outcomes for INTEGRIS-IPF were not related to efficacy, exploratory efficacy analyses included changes in FVC and biomarkers such as PRO-C3, which is raised in patients with IPF and associated with disease progression.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Bexotegrast and IPF outcomes

A total of 21 patients were assigned to the 320mg dose and there was a mean FVC increase of 29.5ml compared to baseline at 12 weeks compared to a decrease of 110.7ml for those assigned to placebo (p < 0.05). Moreover, the mean increase was statistically superior to placebo at all timepoints. In addition, patients receiving 320mg saw a significant reduction in PRO-C3 levels at both week 4 and 12 (p <0.01) compared to placebo.

The press release adds that 24-week data for patients treated with bexotegrast should be available in the second quarter of 2023.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x